Thrombotech - News Flash - Israel
Israeli biotechnology company Thrombotech has obtained US Food and Drug Administration (FDA) approval for a Phase IIa clinical trial of its treatment for ischemic stroke by destroying blood clots. The trial will be conducted in the US and will test the safety of the drug, THR-18. The clinical trial was initiated at Hadassah Medical Center in Jerusalem and Sourasky Medical Center in Tel Aviv. The company is now waiting to receive regulatory permits for trials in Europe and India. View and Share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023

Israeli Startups Raise $1.6B in Q3, Indicating Stabilization - Report
September 27, 2023

Global Chip Maker Buying Renewable Energy From Israeli Firm
September 27, 2023

VC Fund Raises $480M For Cybersecurity Investment
September 26, 2023
Facebook comments